Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Receivables - Net: 2011-2025

Historic Receivables - Net for Lineage Cell Therapeutics (LCTX) over the last 13 years, with Sep 2025 value amounting to $127,000.

  • Lineage Cell Therapeutics' Receivables - Net fell 68.64% to $127,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $127,000, marking a year-over-year decrease of 68.64%. This contributed to the annual value of $638,000 for FY2024, which is 14.36% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Receivables - Net of $127,000 as of Q3 2025, which was down 50.39% from $256,000 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Receivables - Net ranged from a high of $50.8 million in Q4 2021 and a low of $77,000 during Q1 2024.
  • For the 3-year period, Lineage Cell Therapeutics' Receivables - Net averaged around $343,091, with its median value being $256,000 (2025).
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Receivables - Net was 20,908.26% (2021), while the steepest drop was 99.55% (2021).
  • Over the past 5 years, Lineage Cell Therapeutics' Receivables - Net (Quarterly) stood at $50.8 million in 2021, then crashed by 99.41% to $300,000 in 2022, then skyrocketed by 148.33% to $745,000 in 2023, then fell by 14.36% to $638,000 in 2024, then slumped by 68.64% to $127,000 in 2025.
  • Its Receivables - Net was $127,000 in Q3 2025, compared to $256,000 in Q2 2025 and $213,000 in Q1 2025.